Kedudukan dalam Saham
#40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Harga Saham
$0.00162013
Disegerakkan terakhir: 2025-01-03
Perubahan (1 tahun)
0.00%
Perdagangan Cyxone AB (publ) (CYXO)
Harga CYXO dengan permodalan pasaran b
Modal pasaran bagi Cyxone AB (publ)(CYXO)
Modal Pasaran: $156.25K
Sehingga August 2026, Cyxone AB (publ) mempunyai modal pasaran sebanyak $156.25K. Ini menjadikan Cyxone AB (publ) syarikat ke-40403rd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Cyxone AB (publ) dari 2016 hingga 2026
CYXO berbanding dengan 5 teratas yang paling popular stocks
| Harga CYXO |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.470T
|
+3,500,444,002.38%
|
|
|
|
|
$4.467T
|
+2,858,876,405.30%
|
|
|
|
|
$4.174T
|
+2,671,561,324.47%
|
|
|
|
|
$3.700T
|
+2,368,008,737.69%
|
|
|
|
|
$2.854T
|
+1,826,747,876.55%
|
